---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-22-000136"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:43:49.165100+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Selecta Q3 net loss narrows to $7.9M; cash runway to mid-2024

## Summary
- Net loss of $7.9M ($0.05 per share) vs $17.9M loss in Q3 2021; collaboration revenue $20.7M.
- Cash, equivalents & securities total $148.0M as of Sep 30, 2022; expected runway into mid-2024.
- Received $10M milestone from Sobi for DISSOLVE II enrollment and $6M from Sarepta for DMD/LGMD.
- Topline data from Phase 3 DISSOLVE (SEL-212 for chronic gout) expected in Q1 2023.
- Phase 1 trial of SEL-302 (MMA gene therapy) on track to begin Q4 2022; IL-2 and IgA protease candidates by year-end.

## SEC filing metadata
- accession: 0001453687-22-000136
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368722000136/0001453687-22-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368722000136/selb-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-22-000136
- JSON: https://secwatch.observer/filing/0001453687-22-000136.json
- Plain text: https://secwatch.observer/filing/0001453687-22-000136.txt

## Key facts
- Earnings Releases
  Cartesian Therapeutics, Inc. reported financial results for quarter ended September 30, 2022.
  - Period: quarter ended September 30, 2022
  - Result: reported results
  source text: Selecta Biosciences, Inc. announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368722000136/0001453687-22-000136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.